Authors
Latest:
Dr McKenzie on Updates to ASCO Treatment Guidelines in Metastatic Breast CancerAndrew McKenzie, PhD, discusses the updates to the ASCO clinical practice guidelines for biomarker testing in patients with metastatic breast cancer.
Latest:
Novel HER2-Targeted Therapies for NSCLCClosing out their discussion, the panel highlights investigational therapies in NSCLC to look out for.
Latest:
Dr. Politi on Drug-Tolerant Persister Cells in Cancer CareKaterina Politi, PhD, discusses drug-tolerant persister cells in patients with cancer.
Latest:
Emerging Therapies for the Older Patient With Acute Lymphoblastic LeukemiaDr. Shah and faculty provide updates on emerging therapies, which exhibit promise for the treatment of relapsed or refractory acute lymphoblastic leukemia such as tisagenlecleucel and Obe-cel; obecabtagene autoleucel, preliminary outcomes of which were presented in the FELIX study at the 65th ASH Annual Meeting.
Latest:
Genetic Counseling for Patients with Non-Clear Cell RCCThe panel closes their discussion with a look at the standards for genetic counseling for patients with non-clear cell RCC.
Latest:
Dr. Ghidini on the Effects of Body Weight Loss in Gastric/GEJ CancerMichele Ghidini, MD, PhD, discusses the effects of body weight loss in gastric/gastroesophageal junction cancer.
Latest:
Dr. Niemann on Notable Findings from the GLOW Trial in CLLCarsten Niemann, MD, PhD, discusses notable data on patient survival outcomes, as well as the impact of minimal residual disease in the peripheral blood from the phase 3 GLOW trial in patients with chronic lymphocytic leukemia.
Latest:
Disparities in Multiple Myeloma Care: The Path Toward Health EquityExpert panelists share their closing thoughts on the path to improve health equity in multiple myeloma management for racial and ethnic minority groups.
Latest:
Dr. Treon on the Evolution of BTK Inhibitors in Waldenström MacroglobulinemiaSteven P. Treon, MD, PhD, discusses the role of BTK inhibitors in Waldenström macroglobulinemia.
Latest:
Dr McArthur on Neoadjuvant Pembrolizumab Plus Chemotherapy in ER+/HER2– Breast CancerHeather Lynn McArthur, MD, MPH, discusses the primary results from the phase 3 KEYNOTE-756 study of neoadjuvant pembrolizumab plus chemotherapy in early-stage, high-risk, estrogen receptor–positive, HER2-negative breast cancer.
Latest:
Dr Hutson on the Final OS Analysis of the CLEAR Study in Advanced RCCThomas Hutson, DO, discusses the final prespecified overall survival analysis of the phase 3 CLEAR study in patients with advanced renal cell carcinoma.
Latest:
Dr Ip on the Implications of NGS Plus Machine Learning for Diagnosing Hematologic MalignanciesAndrew Ip, MD, discusses the implications of using next-generation sequencing alongside machine learning in the diagnosis of hematologic malignancies.
Latest:
Dr. Tkaczuk on the Utilization of Trastuzumab Deruxtecan in HER2+ Breast CancerKatherine Tkaczuk, MD, discusses the utilization of trastuzumab deruxtecan in HER2-positive breast cancer.
Latest:
Unmet Needs and Looking Ahead in Essential ThrombocythemiaUnmet needs and current areas that are being studied in in essential thrombocythemia.
Latest:
Dr Islam on Treatment of Patients With Hodgkin Lymphoma With or Without HIVJessica Yasmine Islam, PhD, MPH, discusses the treatment of patients with Hodgkin’s lymphoma who do or do not have HIV.
Latest:
Dr. Pavel on the PFS With Lanreotide Autogel in the CLARINET FORTE TrialMarianne Pavel, MD, discusses the progression-free survival of patients with pancreatic and midgut neuroendocrine tumors who are treated with lanreotide autogel in the phase 2 CLARINET FORTE trial.
Latest:
Not All Stage I and II Endometrial Cancers Are AlikeA recent retrospective study found that patients with endometrial cancer in International FICO stage I high- intermediate risk subgroups with fewer than 2 risk factors had a greater than 95% cause-specific survival at 3-year follow-up, and subgroups with 2 or more risk factors had poorer outcomes.
Latest:
Dr. Ross on Toxicity Concerns With Combination Therapies in EGFR+ NSCLCHelen J. Ross, MD, discusses toxicity concerns with combinations therapies in EGFR-mutant non–small cell lung cancer.
Latest:
Dr Hernandez-Ilizaliturri on the Potential Advantages of Iopofosine I 131 in Waldenström MacroglobulinemiaFrancisco Hernandez-Ilizaliturri, MD, discusses the unique potential advantages of the radiotherapeutic iopofosine I 131 in Waldenström macroglobulinemia.
Latest:
Dr Ahluwalia on Advancements in the Management of Brain MetastasesManmeet Singh Ahluwalia, MD, MBA, FASCO, discusses how advancements in precision medicine have improved outcomes for patients with brain metastases.
Latest:
Dr. Usmani on the Rapidly Evolving Landscape in Multiple MyelomaSaad Z. Usmani, MD, MBA, FACP, discusses the rapidly evolving treatment landscape in multiple myeloma.
Latest:
Dr Lee on the Rationale for Investigating Linvoseltamab in R/R Multiple MyelomaHans Lee, MD, discusses the rationale for the phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory multiple myeloma.
Latest:
New Framework for Genetic Testing in Prostate Cancer Takes ShapeIn recent years, great progress has been made in understanding the genetics of metastatic prostate cancer which has translated into the development of new precision therapies.
Latest:
New Breast Center at UI Health Care Aims to Ease the Cancer Journey for PatientsThe new breast center at UI Holden Comprehensive Cancer Center aims to make the cancer journey easier and less stressful for patients by providing access to the state's most advanced cancer services in 1 convenient location.
Latest:
Dr Cobain on the Importance of Molecular Testing in Metastatic Breast CancerErin Frances Cobain, MD, discusses the importance of molecular testing in patients with metastatic breast cancer.
Latest:
Dr Foldi on the Evolving Role of T-DXd in HER2+ Breast CancerJulia Foldi, MD, PhD, discusses the evolving role of treatment with T-DXd in metastatic HER2-positive breast cancer.
Latest:
Dr Kouzy on the Creation of a Centralized Resource to Inform AI Use in Radiation OncologyRamez Kouzy, MD, discusses efforts to improve knowledge of the use of AI in radiation oncology through the creation of an online repository.
Latest:
ALINA: Efficacy and Safety of Adjuvant Alectinib Versus Chemotherapy in Patients With Early-Stage ALK+ NSCLCBenjamin Solomon, MBBS, PhD, FRACP, presents key data from the ALINA study investigating alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).
Latest:
Dr. Ali on Key Findings From the Phase 1 Study of Selinexor Plus Ruxolitinib in MyelofibrosisHaris Ali, MD, discusses a phase 1 dose-escalation trial investigating the administration of selinexor in combination with ruxolitinib for patients with treatment-naïve myelofibrosis.
